Drugs / Prospekta
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05074888 | Oct 2021 → Jun 2022 | long COVID-19 | Materia Medica Holding | Completed | Met primary |
| Phase 3 | NCT04552041 | Dec 2020 → Sep 2022 | vascular dementia | Materia Medica Holding | Completed | Met primary |
| Phase 3 | NCT04569357 | Nov 2020 → Feb 2022 | attention deficit-hyperactivity disorder | Materia Medica Holding | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prospekta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04569357 ↗ |
| Route | Oral | “Oral administration.” NCT04552041 ↗ |